TickerFacts.

Arcus Biosciences, Inc. (RCUS): Long-Term Debt

Annual figures by period end, from SEC filings.

$99.00M
As of 2025-12-31
$101.00M
As of 2026-06-30
2023-12-31: $02024-12-31: $48.00M2025-12-31: $99.00M$99.00M
2023-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$99.00M+106.3%2026-02-25, Balance as of period end
2024-12-31$48.00Mn/a2026-02-25, Balance as of period end
2023-12-31$0n/a2025-02-25, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Arcus Biosciences, Inc. (RCUS)2025-12-31$99.00M+106.3%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$48.25M+24.7%
Arvinas, Inc. (ARVN)2025-12-31$600.0K-25.0%
Puma Biotechnology, Inc. (PBYI)2025-12-31$22.68M-66.7%
Harrow, Inc. (HROW)2025-12-31$250.00M-4.8%
Xeris Biopharma Holdings, Inc. (XERS)2025-12-31$220.34M-5.1%
Evolus, Inc. (EOLS)2025-12-31$146.10M+20.2%
Maravai Lifesciences Holdings, Inc. (MRVI)2025-12-31$291.77M-1.4%
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$209.09M+3.8%

Compare RCUS, AKBA, ARVN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗